Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vraylar
Pharma
Intra-Cellular closing in on major depression nod for Caplyta
Intra-Cellular's surging antipsychotic Caplyta has scored again with remarkable trial results, fueling its bid for its third indication—depression.
Kevin Dunleavy
Jun 18, 2024 11:40am
The top 10 pharma drug ad spenders for 2023
Jun 3, 2024 3:00am
AbbVie to tap Vraylar messaging lessons for Cerevel drug
Dec 8, 2023 6:07am
AbbVie gives Vraylar ad campaign 'a lift' with new focus
May 9, 2023 9:40am
AbbVie's Vraylar approved to treat major depressive disorder
Dec 19, 2022 11:01am
AbbVie seeks Vraylar expansion into depression, eyes $4B+ sales
Feb 23, 2022 10:35am
